literature

HIV mutation literature information.

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.

PMID: 22733652 2012 The Journal of antimicrobial chemotherapy

Abstract: Mutations in the protease gene significantly selected between baseline and failure were L10V, K20R, L33F, M36I, I47V, I54V, A71V and I85V (P < 0.05).

Capturing the reaction pathway in near-atomic-resolution crystal structures of HIV-1 protease.

PMID: 22963370 2012 Biochemistry

Abstract: Structures of wild-type protease and two mutants (PR(V32I) and PR(I47V)) with V32I and I47V substitutions, which are common in drug resistance, reveal the gem-diol tetrahedral intermediate, the separating N- and C-terminal products, and the C-terminal product of an autoproteolytic peptide.

Abstract: The two products in the complex with mutant PR(I47V) have a 2.2 A separation of the amide and carboxyl carbon of the adjacent ends, suggesting partial cleavage prior to product release.

Introduction: Drug resistant mutation I47V is located in the flexible flap and interacts with inhibitor.

Introduction: Mutation

PMID: 21107269 2011 Journal of acquired immune deficiency syndromes (1999)

Abstract: In contrast, M46L and I47V showed good CTL recognition in nearly all patients.

Abstract: Recently, we identified KMIGGIGGF (KF9) as a HLA-B*1501-restricted CTL epitope, including several major PI resistance mutations (M46I/L, I47A/V, G48V, I50V).

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

PMID: 21314993 2011 AIDS research and therapy

Table: I47V

Drug resistance mutations in patients infected with HIV-2 living in Spain.

PMID: 21558334 2011 The Journal of antimicrobial chemotherapy

Abstract: No major mutations associated with drug resistance in HIV-1 were recognized in 29 PR, 20 RT and 5 INT sequences from antiretroviral-naive HIV-2 individuals, although natural polymorphisms with potential effects on susceptibility to PR inhibitors were recognized at 10 positions (L10V/I, V32I, M36I, M46I, I47V, Q58E, A71V/I, G73A, V82I and L89I/V) and for nucleoside reverse transcriptase inhibitors at three positions (T69N, V75I

HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

PMID: 21633285 2011 AIDS (London, England)

Result: The major PI mutations M46I/L and I47V were present in 4 samples, and minor PI mutations L10I/V, V11I, A71T, I85V, and N88D were also detected.

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

PMID: 21685536 2011 Antiviral therapy

Abstract: The DRV-2009 score V11I+L33F+R41K+I47V+2*I50V+2*I54M+K55R+D60E+L74P+L76V+N88D+2*L89V-L10I/V-I13V-G16E-G48V-F53I/L-I62V-I66F-V77I (<0 indicating susceptibility, 0-1 intermediate resistance and >=2 resistance) correlated with VR in the derivation set (n=132, R=0.395; P<0.001).

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

PMID: 21896904 2011 Antimicrobial agents and chemotherapy

Abstract: IVRS performed with r13025, a multiple-PI-resistant recombinant clinical isolate, and TMC310911 selected for mutations L10F, I47V, and L90M (FC in TMC310911 EC(50) = 16).

Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.

PMID: 22110581 2011 PloS one

Table: I47V

Discussion: V32I, I47V, L76V) was relatively low and this could have influenced the covariate selection for our score.

HIV drug resistance surveillance using pooled pyrosequencing.

PMID: 20174661 2010 PloS one

Table: I47V